» Articles » PMID: 27797265

Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer

Overview
Specialty Oncology
Date 2016 Nov 1
PMID 27797265
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Despite the fact that ovarian cancer is the seventh most common cancer in women worldwide and the fth leading cause of cancer death, It is the most common cause of death due to reproductive cancers in Thailand where epithelial ovarian cancer (EOC) is commonly found. According to a Thai statistical analysis in 2010 by the Department of Medical Services, epithelial ovarian cancer was the sixth most common cancer in Thailand from 2001 to 2003.The incidence of 5.1 per 100,000 women per year. Human epididymis protein 4 (HE4) is a novo diagnostic tumor marker for EOC. The combination of HE4 and carcinoma antigen 125 (CA 125) is a tool for detecting epithelial ovarian cancer (EOC) better than using CA 125 alone. Therefore, the researcher is interested in HE4 does have a role to predict recurrent epithelial ovarian cancer.

Materials And Methods: The patients who had complete response after diagnosed with epithelial ovarian cancer by pathology, FIGO stage 3 or more had been treated through surgery and chemotherapy at the Sunpasitthiprasong Hospital from June 2014 until March 2016. The patients were followed up every three months, using tumor marker (CA 125, HE4,Carcinoma antigen 19-9) together with other checkup methods, such as rectovaginal examination, CXR every year and other imaging as indication. Afterwards, the data was analyzed for the ability of HE4 to detect recurrence of epithelial ovarian cancer.

Results: In 47 patients in this study follow-up for 22 months after complete response treatment from surgery and chemotherapy in epithelial ovarian cancer, 23 had recurrent disease and HE4 titer rising .The patients with recurrent epithelial ovarian cancer demonstrated high levels of both HE4 and CA125 with sensitivity of 91.3% and 52.7% respectively, speci city of 87.5% and 95.6% and positive predictive values of 87.5% and 85.7% . HE4 can predict recurrent epithelial ovarian cancer (p-value=0.02242). Comparing HE4 and CA125 in predicting recurrent epithelial ovarian cancer HE4 had more potential than CA125 (p-value =0.8314).

Conclusions: The present study showed HE4 to have a role in predicting recurrent epithelial ovarian cancer and HE4 is potentially better than CA125 as a marker for this purpose.

Citing Articles

Evaluation of follow-up observation using human epididymis protein 4, a tumor marker, in patients with ovarian cancer.

Uno M, Matsuo R, Maezawa N, Kato T Obstet Gynecol Sci. 2023; 66(4):290-299.

PMID: 37380167 PMC: 10375218. DOI: 10.5468/ogs.23024.


Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine.

Kight E, Hussain I, Bowden A, Haselton F Sci Rep. 2021; 11(1):21945.

PMID: 34754053 PMC: 8578327. DOI: 10.1038/s41598-021-01544-4.


DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway.

Liu S, Lin X, Xu Y, Shen Z, Pan W J Ovarian Res. 2018; 11(1):90.

PMID: 30336783 PMC: 6193355. DOI: 10.1186/s13048-018-0462-4.


Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.

Capriglione S, Luvero D, Plotti F, Terranova C, Montera R, Scaletta G Med Oncol. 2017; 34(9):164.

PMID: 28825178 DOI: 10.1007/s12032-017-1026-y.